TILS.L Regulatory News (TILS)

25 Apr 2008 13:35

ReGen Therapeutics PLC25 April 2008 25 April 2008 for immediate release ReGen Therapeutics Plc('ReGen' or the 'Company' - AIM: RGT) Full Scientific Review of ReGen's ColostrininTM published in Journal ofAlzheimer's Disease confirms its potential benefits in the prevention andtreatment of neurodegenerative disorders. ReGen Therapeutics Plc ('ReGen' or the 'Company') announces that a full reviewof the extensive science behind its product ColostrininTM, has been todaypublished online in the Journal of Alzheimer's Disease.* This review states thatwhen given orally ColostrininTM has been shown to have a stabilising effect oncognitive functions in improving the conditions of patients suffering from mildto moderate Alzheimer's disease. This review concludes that, whilst furtherextensive studies are required to understand the mechanism by whichColostrininTM exerts its biological effects, ColostrininTM clearly has potentialbenefit in the prevention and treatment of neurodegenerative disorders. ColostrininTM is marketed in North America and Australia under the brand nameCogniSureTM as a nutritional supplement to 'support healthy brain aging andcognition' in humans** and is available through the professional channel ofhealthcare practitioners such as chiropractors and doctors. The product isexpected to be launched in the European Union in 2008. Summarising this publication Dr. Marian Kruzel *** a co-author of the reportsaid: 'This is a most comprehensive review regarding the potential utility ofColostrininTM in neurodegenerative disorders. It includes research into thenovel mechanisms of action involved in neuroprotection and clearly presentsColostrinin'sTM biodiversity. This is the whole story of the potential ofColostrinin'sTM proactive function in age-associated mental capacity." Percy Lomax, Chairman and Chief Executive Officer of ReGen said: 'This review paper demonstrates the hard scientific evidence concerning theactivity of ColostrininTM. This amount of scientific evidence is unusual for anutraceutical and should support the further development of our marketingplatform. We would also stress that this paper adds weight to our view of thelikely potential of our ColostrininTM derived peptide programme to produce apharmaceutical product that will be used in the treatment of neurodegenerativediseases." For further information: ReGen Therapeutics PlcPercy LomaxTel No 020 7153 4920 Roland Cornish/Felicity GeidtBeaumont Cornish LimitedTel No 020 7628 3396 David Scott/Nick BealerAlexander David SecuritiesLimitedTel No 020 7448 9800 Adrian Duffield/Jon DaviesCollege Hill AssociatesTel No 020 7457 2020 * Istvan Boldogh and Marian L. Kruzel, Journal of Alzheimer's Disease Vol. 13, Number 3, April 2008 p323-331, web address: www.j-alz.com/ **ColostrininTM for use as a human nutraceutical is licensed in North America and Australasia to Metagenics Inc. of San Clemente, California (www.Metagenics.com). Discussions are ongoing with potential distributors in other regions of the world. ***Professor Marian L Kruzel PhD is ReGen's Chief Scientific Consultant and is a faculty member of the Department of Integrative Biology and Pharmacology, The University of Texas, Medical School at Houston. He is an internationally recognized immunologist with an established interest and expertise in inflammation and age-related pathophysiology. Notes for Editors: Abstract of the Full Scientific Review: Colostrum-derived proline-rich polypeptide, also known as ColostrininTM (CLN),has been shown to have a stabilizing effect on cognitive function in Alzheimer'sdisease (AD) patients. This complex action of CLN could be related to preventionof amyloid-b peptide aggregation, as shown in in vitro studies, and its impacton delicate cassettes of signalling pathways common to cellular redoxregulation, proliferation and differentiation. Studies on cultured cells showedthat CLN modulates intracellular levels of reactive oxygen species (ROS), viaregulating glutathione metabolism, activity of antioxidant enzymes andmitochondria function. Due to an improvement in senescence-associatedmitochondrial dysfunction and a decrease in ROS generation, CLN decelerates theaging processes of both cultured cells and experimental animals. When givenorally to mice, CLN increased the life-span and improved various motor andsensory activities. Although the molecular basis by which CLN exerts its diverseeffects are still under investigation, the regulatory effect on the cellularredox state via maintenance of mitochondrial function and modification of ROS-induced cell signalling seem to be of great importance. In this article, weexamine experimental data pertinent to the mechanism of action, including areview of CLN's utility in the maintenance of physiological processes in whichoxidative stress has an etiological role. Keywords: Proline-rich polypeptide, immunomodulation, Alzheimer's disease, agerelated disorders, amyloid-b, oxidative stress About ReGen Therapeutics ReGen Therapeutics PLC is a UK-based biopharmaceutical company engaged in theacquisition and development of therapies related to age related disordersincluding Alzheimer's disease, Parkinson's disease and other degenerativeneurological disorders. The Company is focused particularly on technologies that address large unmetmedical need to maintain healthy brain ageing, as well as rehabilitation aftertraumatic brain injury. ReGen's product pipeline comprises ColostrininTM anutraceutical that is in full commercial production and had been launched to theprofessional channel in the USA and Australia under the brand name CogniSureTM;a drug development programme based on ColostrininTM-derived peptides; and PhaseII clinical trials on a novel formulation of Zolpidem for the treatment of braintrauma and reversal of dormancy. This information is provided by RNS The company news service from the London Stock Exchange